Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226661 · ClinicalTrials.gov registry record · Phase 2
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
A Phase 2 study, sponsored by Supernus Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
NCT07226661 is a Phase 2 study that is actively recruiting participants, run by Supernus Pharmaceuticals. The registered enrollment target is 230 participants.
The verdict
NCT07226661, a Phase 2 study, is actively recruiting participants, sponsored by Supernus Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder
Interventions
- DRUG Placebo
- DRUG SPN-821 2400 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2026-01-19 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07226661
The ClinicalTrials.gov registry entry for NCT07226661 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07226661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07226661 about?
NCT07226661 is a clinical study titled "Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder". This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder
What is the current status of trial NCT07226661?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2026-01-19. Estimated completion is 2027-01-31.
What interventions are being tested in trial NCT07226661?
The interventions under investigation include: Placebo (DRUG), SPN-821 2400 mg (DRUG).
Who is sponsoring clinical trial NCT07226661?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.